Experiment 1219574
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Empty organism |
| Citation | KAHN,JO: KAPLAN,LD: GAMBERTOGLIO,JG: BREDESEN,D: ARRI,CJ: TURIN,L: KIBORT,T: WILLIAMS,RL: LIFSON,JD: VOLBERDING,PA:. (1990). THE SAFETY AND PHARMACOKINETICS OF GLQ223 IN SUBJECTS WITH AIDSAND AIDS-RELATED COMPLEX: A PHASE I STUDY.. 4(12) |
| Amount utilized | |
| Compound isolated | |
| Disease | THIS WAS THE RESULT OF A PHASE I DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF A SINGLE INTRAVENOUS INFUSION OF THE TITLE COMPOUND IN SUBJECTS WITH AIDS AND ARC. 18 SUBJECTS WERE ENROLLED IN THE STUDY, 10 WITH AIDS AND 8 WITH ARC. ALL SUBJECTS WERE MONITORED FOR TOLERANCE AND TOXICITY. IMMUNOLOGICAL AND VIROLOGICAL PARAMETERS WERE ALSO FOLLOWED. THE COMPOUND WAS NOT ASSOCIATED WITH NOTABLE TOXICITY WITH THE EXCEPTION OF 1 PATIENT WHO EXPERIENCED A SEVERE NEUROLOGICAL ADVERSE REACTION. NO CONSISTENT OR SUSTAINED CHANGES IN CD4+ LYMPHOCYTE POPULATIONS OR HIV ANTIGEN LEVELS WERE OBSERVED. SERUM CONCENTRATIONS OF THE TITLE COMPOUND THAT WERE COMPARABLE TO CONCENTRATIONS SHOWN TO HAVE ANTIVIRAL EFFECTS IN VITRO WERE ACHIEVED TRANSIENTLY, BUT MAY NOT HAVE BEEN MAINTAINED FOR A SUFFICIENT DURATION TO EXERT ANTIRETROVIRAL EFFECTS. |
| Dose amount | 1.36 MCG |
| Number | 1 |
| Qualitative result | INACTIVE |
| Animal | HUMAN ADULT |
| Per unit | KG |
| Dose expression | DOSE |